Friday, May 10, 2024 10:32:03 AM
Recent CTMX News
- CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/22/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:36:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:34:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:32:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 09:31:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:01:57 PM
- CytomX Therapeutics Announces New Employment Inducement Grants • GlobeNewswire Inc. • 05/16/2024 08:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/13/2024 08:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:41:03 PM
- CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 08:10:00 PM
- CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager) • GlobeNewswire Inc. • 05/08/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:04:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:21 PM
- CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab) • GlobeNewswire Inc. • 05/07/2024 08:15:00 PM
- CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024 • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/11/2024 08:30:38 PM
- CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/11/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:02:08 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 08:00:31 PM
- U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher • IH Market News • 03/11/2024 10:39:47 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM